Characterization of genetically modified human embryonic kidney 293 cells lacking equilibrative nucleoside transporter subtype 2, or both subtypes 1 and 2, and the impact of their loss on sensitivity to chemotherapeutic purine/pyrimidine analogs. [PDF]
Shahid N, Hammond JR.
europepmc +1 more source
Using pharmacogenomics to personalise drug therapy: which drugs, when and how. [PDF]
Stocker SL, Polasek TM.
europepmc +1 more source
Determining variant effects with pooled prime editing. [PDF]
Kajba CM, Herger M.
europepmc +1 more source
Genetic Determinants of Hematopoietic Toxicity Risk in Thai Pediatric Patients Undergoing 6-Mercaptopurine Treatment. [PDF]
Khaeso K +8 more
europepmc +1 more source
The Effectiveness and Safety of First-Line Thioguanine in Thiopurine-Naïve Inflammatory Bowel Disease Patients. [PDF]
Crouwel F +10 more
europepmc +1 more source
Nucleobase catalysts for the enzymatic activation of 8-oxoguanine DNA glycosylase 1. [PDF]
Hank EC +31 more
europepmc +1 more source
All-component-active metal-organic frameworks for tailored chemoradiotherapy of self-defensive tumors. [PDF]
Xu X +6 more
europepmc +1 more source
Adsorption of drugs on B12N12 and Al12N12 nanocages. [PDF]
Geetha Sadasivan Nair R +2 more
europepmc +1 more source
Thiopurine therapy enhances immune checkpoint inhibitor efficacy in low-mutational burden melanoma: A promising anticancer approach. [PDF]
Nazerai L +4 more
europepmc +1 more source

